These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11989055)

  • 1. [Screening and intervention. A strategy in type 2 diabetes?].
    Jørgensen T; Glümer C; Borch-Johnsen K
    Ugeskr Laeger; 2002 Apr; 164(16):2135-9. PubMed ID: 11989055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of type 2 diabetes screening: results from recently published studies.
    Icks A; Rathmann W; Haastert B; John J; Löwel H; Holle R; Giani G;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S167-71. PubMed ID: 16032536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of screening of all newly recruited employees for diabetes at a tertiary care hospital.
    Ali NS; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2007; 19(2):23-5. PubMed ID: 18183713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using an economic model of diabetes to evaluate prevention and care strategies in Australia.
    Colagiuri S; Walker AE
    Health Aff (Millwood); 2008; 27(1):256-68. PubMed ID: 18180502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
    Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for diabetes.
    Backholer K; Chen L; Shaw J
    Pathology; 2012 Feb; 44(2):110-4. PubMed ID: 22228253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finding undiagnosed type 2 diabetes: is it worth the effort?
    Engelgau MM; Narayan KM
    Eff Clin Pract; 2001; 4(6):281-3. PubMed ID: 11769302
    [No Abstract]   [Full Text] [Related]  

  • 9. [Opportunistic screening for diabetes in primary health care. Life style changes can prevent diabetes mellitus among individuals at risk].
    Hagström B
    Lakartidningen; 2002 Apr; 99(16):1852. PubMed ID: 12043490
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of diabetes mellitus type 2].
    Baan CA; Feskens EJ
    Ned Tijdschr Geneeskd; 2001 Sep; 145(35):1677-80. PubMed ID: 11561483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for type 2 diabetes in the Iranian national programme: a preliminary report.
    Azizi F; Guoya MM; Vazirian P; Dolatshati P; Habbibian S
    East Mediterr Health J; 2003; 9(5-6):1122-7. PubMed ID: 16450546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Foos V; Lurati FM; Lammert M; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of type 2 diabetes prevention.
    Kissimova-Skarbek K
    Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
    [No Abstract]   [Full Text] [Related]  

  • 17. Maximizing efficiency and cost-effectiveness of Type 2 diabetes screening: the AusDiab study.
    Chen L; Magliano DJ; Balkau B; Wolfe R; Brown L; Tonkin AM; Zimmet PZ; Shaw JE
    Diabet Med; 2011 Apr; 28(4):414-23. PubMed ID: 21392062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.
    Hoerger TJ; Hicks KA; Sorensen SW; Herman WH; Ratner RE; Ackermann RT; Zhang P; Engelgau MM
    Diabetes Care; 2007 Nov; 30(11):2874-9. PubMed ID: 17698614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the price of life and why doesn't it increase at the rate of inflation?
    Ubel PA; Hirth RA; Chernew ME; Fendrick AM
    Arch Intern Med; 2003 Jul; 163(14):1637-41. PubMed ID: 12885677
    [No Abstract]   [Full Text] [Related]  

  • 20. The cost of screening for diabetes and intermediate hyperglycaemia.
    Colagiuri S
    Diabetes Res Clin Pract; 2012 Sep; 97(3):341-2. PubMed ID: 22682947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.